Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine

F1000Res. 2023 Aug 10:11:487. doi: 10.12688/f1000research.120821.2. eCollection 2022.

Abstract

Background: Buprenorphine, a partial agonist of the mu-opioid receptor, is an increasingly prescribed medication for maintenance treatment of opioid use disorder. When this medication is taken in the context of active opioid use, precipitated withdrawal can occur, leading to acute onset of opioid withdrawal symptoms. Fentanyl complicates use of buprenorphine, as it slowly releases from body stores and can lead to higher risk of precipitated withdrawal. Objectives: Describe the successful management of buprenorphine precipitated opioid withdrawal from fentanyl with high doses of buprenorphine. We seek to highlight how no adverse effects occurred in this patient and illustrate his stable transition to outpatient treatment. Case report: We present the case of a patient with severe opioid use disorder who presented in moderately severe opioid withdrawal after taking non-prescribed buprenorphine-naloxone which precipitated opioid withdrawal from daily fentanyl use. He was treated with high doses of buprenorphine, 148 mg over the first 48 hours, averaging 63 mg per day over four days. The patient reported rapid improvement in withdrawal symptoms without noted side effects and was able to successfully taper to 16 mg twice daily by discharge. Conclusions: This case demonstrates the safety and effectiveness of buprenorphine at high doses for treatment of precipitated withdrawal. While other options include symptomatic withdrawal management, initiating methadone or less researched options like ketamine, utilizing buprenorphine can preserve or re-establish confidence in this life-saving medication. This case also increases the previously documented upper boundary on buprenorphine dosing for withdrawal and should provide additional confidence in its use.

Keywords: Buprenorphine; Opioid-Related Disorders; case report; fentanyl.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Buprenorphine* / administration & dosage
  • Buprenorphine* / adverse effects
  • Buprenorphine* / therapeutic use
  • Fentanyl* / administration & dosage
  • Fentanyl* / adverse effects
  • Fentanyl* / therapeutic use
  • Humans
  • Male
  • Opiate Substitution Treatment / adverse effects
  • Opioid-Related Disorders / drug therapy
  • Substance Withdrawal Syndrome* / drug therapy

Substances

  • Fentanyl
  • Buprenorphine

Grants and funding

Funding: N.L.B. was supported by the University of Iowa Carver College of Medicine Physician Scientist Training Pathway, Iowa City, IA. A.L. was supported by grants from the Iowa Department of Public Health State Opioid Response Corrections Liaison and SBIRT (5881SA144E, 5881SA145E, and 5881SA137E), Des Moines, IA; the Substance Abuse and Mental Health Services Administration (TI081620), Rockville, MD; and the Health Resources and Services Administration (T25HP37624), Washington, DC.